Incyte (INCY) presented several analyses today from clinical studies of ruxolitinib, an oral...
Monday, December 10, 2012, 7:45 PM ETIncyte (INCY) presented several analyses today from clinical studies of ruxolitinib, an oral Janus kinase inhibitor that's FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis. Long-term results show that patients treated with the drug had improved survival rates over placebo and best available therapy. Additionally, data from ongoing trials suggest that long-term treatment may be an effective therapy for patients with polycythemia vera - a bone marrow disease that leads to an abnormal increase in the number of blood cells - as well.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles